Abstract
A history case of systemic juvenile idiopathic arthritis with early onset and severe clinical case, resistant to treatment with standard immunosuppressive agents is represented in the article. This case demonstrates high clinical efficacy of adalimumab in a patient with severe course of systemic juvenile idiopathic arthritis, prolonged remission of extra-articular involvement and persistent polyarthritis. By the 4 th week of the treatment inflammatory changes in the joints had arrested, range of motions had widened, laboratory markers of activity had normalized and non-active stage of the disease had been established. The duration of the remission of articular syndrome was 2 years, no relapses were observed during the follow-up period.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
